---
document_datetime: 2025-08-20 13:49:09
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/opzelura-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: opzelura-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.2363648
conversion_datetime: 2025-12-23 03:33:14.082943
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Opzelura

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                         |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------|
| Variation type IB /  | C.I.11 Introduction of, or change(s) to, the | 28/07/2025                          | N/A                                         |                                  | To update the due date for study INCB 18424-309 |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000282484                     | obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Change in due date for category 1, 2 or 3 studies in the RMP and/or Annex II - Accepted C.I.11.z (Type IB) - To update the due date for study INCB 18424-309 (category 3) from June 2024 to December 2027 in line with the modified PIP. In addition, the MAH took the opportunity to update the name of the QPPV, and the status of the PASS study INCB88888-037 and study INCB18424-308.                                                                                                                                                                                                                                  |            |             | (category 3) from June 2024 to December 2027 in line with the modified PIP.                                                                                                                                                                                                                                                                                                      |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000256180 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.13 Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority - Accepted Submission of the final report from study INCB 18424-217; this is a safety and efficacy study of ruxolitinib cream combined with narrow-band ultraviolet B phototherapy in participants with vitiligo. Upon CHMP's request, SmPC section 4.5 was revised in line with the submitted data. In addition, changes were also made to the PI to bring it in line with the SmPC guideline, to move the statement related to long-term data from SmPC section 4.8 to 5.1 with related editorial changes, and to include a correction | 03/07/2025 | SmPC and PL | The use of ruxolitinib cream in combination with other topical medicinal products used to treat vitiligo has not been evaluated and co-application on the same skin areas is not recommended. The efficacy and safety of the combination of ruxolitinib cream with narrow-band ultraviolet B (NB-UVB) phototherapy has not been established;thus, no recommendation can be made. |

<div style=\"page-break-after: always\"></div>

|                                       | in Annex IIIA. The package leaflet has been updated accordingly.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |     |                   |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| Variation type IA / EMA/VR/0000273740 | B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 20/05/2025 | N/A |                   |
| Variation type IA /                   | This was an application for a group of variations. A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.b Tightening of specification limits - Accepted B.I.a.4 Change to in-process tests or limits | 10/04/2025 | N/A | EMA/VR/0000265337 |

<div style=\"page-break-after: always\"></div>

| substance - B.I.a.4.b Addition of a new in- process test and limits - Accepted   |
|----------------------------------------------------------------------------------|